Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403)
2024
Phase I/II Study of Neoadjuvant Chemoradiotherapy Consisting of S‑1 and Cisplatin for Patients with Clinically Resectable Type 4 or Large Type 3 Gastric Cancer (OGSG1205)
Phase I study of neoadjuvant chemoradiotherapy with S‑1 for clinicallyresectable type 4 or large type 3 gastric cancer in elderly patients aged75 years and older (OGSG1303)
Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)
大型3型/4型胃癌に対する術前S-1+Oxaliplatin+ Docetaxel併用療法の有効性と安全性確認第II相試験(OGSG1902)短期成績報告
Short‑term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701)
RINDBeRG試験におけるラムシルマブの投与タイミングにおけるサブグループ解析
Effects of an oral elemental nutritional supplement for gastric cancer with adjuvant S-1 therapy(Phase II trial: OGSG1108)
Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery followed by adjuvant docetaxel and S-1 for patients with large type 3 or type 4 gastric cancer: Short-term outcomes of the phase II OGSG1902 trial
高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine+Oxaliplatin療法の第II相試験(OGSG1701)